Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of NXT007 prophylaxis in pediatric hemophilia A
jRCT2051260212Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of zemocimig in hemophilia A, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Annualized number of treated bleeds. Started Nov 2026; status: recruiting.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2051260212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260212.